DNLI — Recent News Coverage
All news mentioning DNLI in ESEN's AI-graded feed
News stories with DNLI as an affected ticker. Each article is graded by ESEN AI for impact level and direction (up/down/flat) on DNLI. See /coverage/DNLI for the 30-day aggregate.
SEEKINGALPHA.COM
·
2026-08-13
NEUTRAL
BULLISH
CORR0.58
Denali Therapeutics: AVLAYAH Converts A Platform Story Into A Commercial One (NASDAQ:DNLI)
$DNLI
◈ ESEN AI
Denali Therapeutics (DNLI) has achieved a meaningful milestone by securing FDA approval for AVLAYAH, marking a strategic inflection from preclinical platform operator to commercial-stage biopharmaceutical company. This …
SEEKINGALPHA.COM
·
2026-08-07
NEUTRAL
NEUTRAL
CORR0.42
Denali Therapeutics Inc. (DNLI) Q2 2026 Earnings Call Transcript
$DNLI
◈ ESEN AI
DNLI's Q2 2026 earnings call represents a standard periodic disclosure event for the biotech sector, providing shareholders with operational updates and financial performance metrics. The earnings transcript itself cont…
SEEKINGALPHA.COM
·
2026-08-07
NEUTRAL
NEUTRAL
CORR0.35
Denali Therapeutics Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:DNLI) 2026-08-07
$DNLI
◈ ESEN AI
DNLI released its Q2 2026 earnings presentation without material headline surprises or disclosed operational shocks. The filing itself represents routine regulatory compliance rather than breaking financial news or guid…
MANILATIMES.NET
·
2026-07-27
LOW
NEUTRAL
CORR0.12
Denali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026
$DNLI
◈ ESEN AI
Denali Therapeutics (DNLI) announced a standard earnings calendar event, scheduling Q2 2026 financial results disclosure for August 6, 2026. This is a routine procedural announcement with no material operational, pipeli…
MANILATIMES.NET
·
2026-06-18
NEUTRAL
BULLISH
CORR0.42
Denali Therapeutics Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million
$DNLI
◈ ESEN AI
Denali Therapeutics (DNLI) monetized a regulatory asset by selling its Rare Pediatric Disease Priority Review Voucher (PRV) for $195 million gross proceeds. This transaction represents a strategic capital deployment mec…
EXPLORE OTHER FILTERS